{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:33:50Z","timestamp":1787009630900,"version":"build-2736575974"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022244","name":"NIHR Applied Research Collaboration West Midlands","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022244","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the incidence and risk of nephrolithiasis in people receiving uricosuric therapies for gout.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A search was conducted using MEDLINE, Embase, Cochrane Library, Web of Science and Clinical Trials.gov electronic databases on 16 May 2023 (updated 10 May 2024). Randomized controlled trials (RCTs) and cohort studies assessing the incidence and\/or risk of nephrolithiasis in adults with gout treated with uricosuric therapies were included (with or without a non-uricosuric urate-lowering therapy [ULT] comparator group). Other designs and studies involving people with asymptomatic hyperuricaemia only were excluded. A random-effects model was used to calculate pooled incidence and risk estimates. Risk of bias assessments were performed for all included studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-three studies (10 RCTs, 13 cohort studies) were included in the meta-analysis (n\u2009=\u200978\u2009042 participants, 15\u2009385 received a uricosuric). The pooled incidence of nephrolithiasis amongst participants taking uricosuric therapies was 3.35% (95% CI 2.03\u20134.92) (Benzbromarone [10 studies] 3.92% [1.89\u20136.52], Lesinurad [6 studies] 3.08% [1.38\u20135.38]). Pooled incidence by study design was 2.87% (95% CI 1.30\u20134.93) in 10 RCTs and 3.93% (1.95\u20136.44) in 13 cohort studies. The pooled risk ratio for nephrolithiasis in participants taking uricosuric therapies vs participants not taking a uricosuric (other ULT and\/or placebo) (nine studies) was 1.63 (95% CI 1.33\u20132.00, P = 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nephrolithiasis is a common side effect of uricosuric therapies, although the quality of evidence for this is low-moderate due to significant heterogeneity and bias. Further research is required to identify those at highest risk, and who may benefit from additional interventions such as urinary alkalinization. Our estimates of incidence of nephrolithiasis and associated risk can lead to more informed shared treatment decisions in the management of gout.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf577","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:40:01Z","timestamp":1761745201000},"source":"Crossref","is-referenced-by-count":3,"title":["Incidence and risk of nephrolithiasis with uricosuric therapies for the treatment of gout: a systematic review and meta-analysis of randomized controlled trials and cohort studies"],"prefix":"10.1093","volume":"65","author":[{"given":"Chanaka","family":"Dahanayake","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Orpington Hospital, King\u2019s College Hospitals NHS Foundation Trust , Orpington,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1227-2703","authenticated-orcid":false,"given":"Ram","family":"Bajpai","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University , Keele,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lambie","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University , Keele,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey M","family":"Jordan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospitals Sussex NHS Foundation Trust , Brighton,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8954-7082","authenticated-orcid":false,"given":"Edward","family":"Roddy","sequence":"additional","affiliation":[{"name":"School of Medicine, Keele University , Keele,","place":["UK"]},{"name":"Haywood Academic Rheumatology Centre, Midlands Partnership University NHS Foundation Trust , Burslem,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"2026022606021654600_keaf577-B1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2026022606021654600_keaf577-B2","doi-asserted-by":"crossref","first-page":"100416","DOI":"10.1016\/j.lanepe.2022.100416","article-title":"Management of gout following 2016\/2017 European (EULAR) and British (BSR) guidelines: an interrupted time-series analysis in the United Kingdom","volume":"18","author":"Russell","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2026022606021654600_keaf577-B3","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/rheumatology\/kex150","article-title":"The British Society for Rheumatology Guideline for the Management of Gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology"},{"key":"2026022606021654600_keaf577-B4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026022606021654600_keaf577-B5","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2026022606021654600_keaf577-B6","first-page":"372","article-title":"The clinical and metabolic effects of Benemid in patients with gout","volume":"64","author":"Talbott","year":"1951","journal-title":"Trans Assoc Am Physicians"},{"key":"2026022606021654600_keaf577-B7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0002-9343(50)90293-2","article-title":"Uric acid metabolism in gout","volume":"9","author":"Gutman","year":"1950","journal-title":"Am J Med"},{"key":"2026022606021654600_keaf577-B8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"2026022606021654600_keaf577-B9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0272-6386(04)01131-X","article-title":"ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention","volume":"44","author":"Jungers","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2026022606021654600_keaf577-B10","first-page":"371","article-title":"Metabolic syndrome and nephrolithiasis: a systematic review and meta-analysis of the scientific evidence","volume":"27","author":"Rendina","year":"2014","journal-title":"J Nephrol"},{"key":"2026022606021654600_keaf577-B11","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4103\/1947-2714.145477","article-title":"The risk of coronary heart disease in patients with kidney stones: a systematic review and meta-analysis","volume":"6","author":"Cheungpasitporn","year":"2014","journal-title":"N Am J Med Sci"},{"key":"2026022606021654600_keaf577-B12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/ki.2010.473","article-title":"Nephrolithiasis-associated bone disease: pathogenesis and treatment options","volume":"79","author":"Sakhaee","year":"2011","journal-title":"Kidney Int"},{"key":"2026022606021654600_keaf577-B13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/bju.14991","article-title":"Evaluation of the economic burden of kidney stone disease in the UK: a retrospective cohort study with a mean follow-up of 19 years","volume":"125","author":"Geraghty","year":"2020","journal-title":"BJU Int"},{"key":"2026022606021654600_keaf577-B14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","article-title":"Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies","volume":"17","author":"Roughley","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2026022606021654600_keaf577-B15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026022606021654600_keaf577-B16","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2026022606021654600_keaf577-B17","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026022606021654600_keaf577-B18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/PXH.0000000000000023","article-title":"Evolution of statistical models for meta-analysis and implications for best practice","volume":"2","author":"Kelley","year":"2023","journal-title":"Curr Opin Epidemiol Public Health"},{"key":"2026022606021654600_keaf577-B19","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Community Health"},{"key":"2026022606021654600_keaf577-B20","doi-asserted-by":"crossref","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"2026022606021654600_keaf577-B21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","article-title":"A new improved graphical and quantitative method for detecting bias in meta-analysis","volume":"16","author":"Furuya-Kanamori","year":"2018","journal-title":"Int J Evid Based Healthc"},{"key":"2026022606021654600_keaf577-B22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of finding tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2026022606021654600_keaf577-B23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12894-022-01161-x","article-title":"Prevalence and risk factors of kidney stone disease in population aged 40-70 years old in Kharameh cohort study: a cross-sectional population-based study in southern Iran","volume":"22","author":"Moftakhar","year":"2022","journal-title":"BMC Urol"},{"key":"2026022606021654600_keaf577-B24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/ndt\/gfac037","article-title":"Factors associated with sex differences in the risk of kidney stones","volume":"38","author":"Ferraro","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026022606021654600_keaf577-B25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.293.4.455","article-title":"Obesity, weight gain, and the risk of kidney stones","volume":"293","author":"Taylor","year":"2005","journal-title":"JAMA"},{"key":"2026022606021654600_keaf577-B26","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"key":"2026022606021654600_keaf577-B27","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"2026022606021654600_keaf577-B28","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026022606021654600_keaf577-B29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13075-018-1788-4","article-title":"Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study","volume":"21","author":"Dalbeth","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026022606021654600_keaf577-B30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026022606021654600_keaf577-B31","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026022606021654600_keaf577-B32","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/imj.13173","article-title":"The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand","volume":"46","author":"Stamp","year":"2016","journal-title":"Intern Med J"},{"key":"2026022606021654600_keaf577-B33","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study","volume":"56","author":"Tausche","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2026022606021654600_keaf577-B34","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3899\/jrheum.121301","article-title":"Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population","volume":"40","author":"Pui","year":"2013","journal-title":"J Rheumatol"},{"key":"2026022606021654600_keaf577-B35","doi-asserted-by":"crossref","first-page":"806710","DOI":"10.3389\/fmed.2021.806710","article-title":"Effect of clinical typing on serum urate targets of benzbromarone in Chinese gout patients: a prospective cohort study","volume":"8","author":"Xue","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026022606021654600_keaf577-B36","author":"ClinicalTrials.gov","year":"2019"},{"key":"2026022606021654600_keaf577-B37","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg\/day versus benzbromarone 100-200 mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026022606021654600_keaf577-B38","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.42266","article-title":"Superiority of low-dose benzbromarone to low-dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion","volume":"74","author":"Yan","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026022606021654600_keaf577-B39","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1093\/rheumatology\/keaa668","article-title":"The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study","volume":"60","author":"Xue","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026022606021654600_keaf577-B40","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/acr.20221","article-title":"Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout","volume":"62","author":"Perez-Ruiz","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026022606021654600_keaf577-B41","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/archinte.1965.03870020052012","article-title":"Urate diuretic therapy in chronic gout: a comparative study of probenecid and sulfinpyrazone","volume":"116","author":"Velayos","year":"1965","journal-title":"Arch Intern Med"},{"key":"2026022606021654600_keaf577-B42","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/art.39684","article-title":"A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout","volume":"68","author":"Poiley","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026022606021654600_keaf577-B43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/art.1780050406","article-title":"Long term uricosuric therapy in gout","volume":"5","author":"Thompson","year":"1962","journal-title":"Arthritis Rheum"},{"key":"2026022606021654600_keaf577-B44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/1529-0131(195906)2:3<193::AID-ART1780020302>3.0.CO;2-8","article-title":"Gout: six-year follow-up on probenecid (benemid) therapy","volume":"2","author":"Bartels","year":"1959","journal-title":"Arthritis Rheum"},{"key":"2026022606021654600_keaf577-B45","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1001\/jama.1961.03040110035008","article-title":"The use of sulfinpyrazone in the treatment of gout","volume":"175","author":"Persellin","year":"1961","journal-title":"JAMA"},{"key":"2026022606021654600_keaf577-B46","first-page":"1371","article-title":"Effets Cliniques et Biologiques de la Benzbromarone chez le Goutteux et l\u2019hyperuricemique","volume":"242","author":"Bied","year":"1979","journal-title":"Lyon Medical"},{"key":"2026022606021654600_keaf577-B47","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"2026022606021654600_keaf577-B48","first-page":"249","article-title":"Goutte et benziodarone [Gout and benziodarone]","volume":"10","author":"Thomas","year":"1967","journal-title":"Rein Foie"},{"key":"2026022606021654600_keaf577-B49","first-page":"701","article-title":"Ten years\u2019 experience with benzbromarone in the management of gout and hyperuricaemia","volume":"59","author":"Masbernard","year":"1981","journal-title":"S Afr Med J"},{"key":"2026022606021654600_keaf577-B50","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1093\/rheumatology\/keae262","article-title":"Risk of urolithiasis associated with allopurinol versus benzbromarone among patients with gout: a population-based cohort study","volume":"63","author":"Kang","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026022606021654600_keaf577-B51","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"2026022606021654600_keaf577-B52","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/art.39254","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"67","author":"Neogi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026022606021654600_keaf577-B53","author":"The Council for International Organizations of Medical Sciences (CIOMS)","year":"1999"},{"key":"2026022606021654600_keaf577-B54","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2147\/CLEP.S370591","article-title":"Global, regional, and national burden of urolithiasis from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"14","author":"Zhang","year":"2022","journal-title":"Clin Epidemiol"},{"key":"2026022606021654600_keaf577-B55","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00345-017-2008-6","article-title":"Epidemiology of stone disease across the world","volume":"35","author":"Sorokin","year":"2017","journal-title":"World J Urol"},{"key":"2026022606021654600_keaf577-B56","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.mayocp.2017.11.018","article-title":"The changing incidence and presentation of urinary stones over 3 decades","volume":"93","author":"Kittanamongkolchai","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"2026022606021654600_keaf577-B57","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-1-4471-4387-1_9","volume-title":"Urolithiasis","author":"Lee","year":"2012"},{"key":"2026022606021654600_keaf577-B58","first-page":"653","article-title":"The occurrence of nephrolithiasis in gout patients: a longitudinal follow-up study using a national health screening cohort","volume":"12","author":"Kim","year":"2022","journal-title":"Life (Basel)"},{"key":"2026022606021654600_keaf577-B59","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13075-017-1376-z","article-title":"Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study","volume":"19","author":"Landgren","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2026022606021654600_keaf577-B60","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1046\/j.1523-1755.2003.t01-2-00171.x","article-title":"The association between gout and nephrolithiasis in men: the health professionals\u2019 follow-up study","volume":"64","author":"Kramer","year":"2003","journal-title":"Kidney Int"},{"key":"2026022606021654600_keaf577-B61","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1056\/NEJM198611273152204","article-title":"Randomized trial of allopurinol in the prevention of calcium oxalate calculi","volume":"315","author":"Ettinger","year":"1986","journal-title":"N Engl J Med"},{"key":"2026022606021654600_keaf577-B62","doi-asserted-by":"crossref","first-page":"e14283","DOI":"10.1111\/ijcp.14283","article-title":"Association of urate-lowering drugs with the risk of future urolithiasis in patients with gout: a population-based nested case-control study","volume":"75","author":"Wu","year":"2021","journal-title":"Int J Clin Pract"},{"key":"2026022606021654600_keaf577-B63","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10067-022-06356-z","article-title":"Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis","volume":"42","author":"Li","year":"2023","journal-title":"Clin Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf577\/65041888\/keaf577.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keaf577\/65041888\/keaf577.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keaf577\/65041888\/keaf577.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:02:34Z","timestamp":1772103754000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf577\/8306841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf577","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,10,30]]},"article-number":"keaf577"}}